Welcome to our dedicated page for Phathom Pharmaceuticals news (Ticker: PHAT), a resource for investors and traders seeking the latest updates and insights on Phathom Pharmaceuticals stock.
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, and its news flow reflects this GI specialization. Company updates frequently center on VOQUEZNA (vonoprazan), a first-in-class potassium-competitive acid blocker (PCAB) that Phathom markets in the United States for adult patients with Erosive GERD, Non-Erosive GERD, and Helicobacter pylori infection in combination regimens.
Investors and healthcare observers following PHAT news can expect regular announcements on commercial performance, including prescription milestones and revenue updates tied to VOQUEZNA tablets, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Phathom’s press releases have highlighted metrics such as total VOQUEZNA prescriptions dispensed in the United States and quarterly financial results, often accompanied by commentary on commercialization strategy and expense trends.
Another major category of Phathom news involves clinical and scientific developments. The company reports progress in trials like the Phase 3 pHalcon-NERD-301 study in Non-Erosive GERD and the Phase 2 pHalcon-EoE-201 study evaluating VOQUEZNA in eosinophilic esophagitis. Publications in peer-reviewed journals and presentations at gastroenterology conferences, such as the American College of Gastroenterology Annual Scientific Meeting, are common topics in its releases.
Phathom also issues news on capital markets activity, including proposed and priced underwritten public offerings of common stock and pre-funded warrants, as well as corporate updates such as leadership appointments and participation in investor conferences. Together, these news items provide a view into the company’s GI-focused strategy, clinical pipeline, commercial trajectory, and financing plans. For users tracking PHAT, the news page offers a consolidated stream of these developments over time.
Phathom Pharmaceuticals (Nasdaq: PHAT) has withdrawn its previously planned public offering, citing adverse market conditions. The company announced a robust balance sheet with cash and equivalents of $225 million as of September 30, 2021, sufficient to fund operations into mid-2023, along with an additional $100 million available under its term loan facility. Phathom is focused on developing novel treatments for gastrointestinal diseases, particularly through its late-stage asset, vonoprazan. However, the cash figures are preliminary and subject to change.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced an underwritten public offering of 5,000,000 shares of common stock, with 4,000,000 shares from Phathom and 1,000,000 shares from Takeda Pharmaceutical Company. An additional 600,000 shares may be purchased by underwriters within 30 days. Proceeds will finance the clinical development and commercialization of vonoprazan, a treatment for gastrointestinal diseases. Phathom will not receive proceeds from shares sold by Takeda. The offering is subject to market conditions.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced data from the Phase 3 PHALCON-HP trial, the largest U.S. trial for H. pylori infection, which received the ACG Governors Award for Excellence in Clinical Research. The study demonstrated that vonoprazan-based therapies had superior eradication rates compared to current standard treatments. Key findings include eradication rates of 84.7% and 78.5% for vonoprazan triple and dual therapies, respectively. The company submitted new drug applications for vonoprazan for H. pylori treatment, highlighting its commitment to addressing unmet medical needs.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced that new data on vonoprazan, a potassium competitive acid blocker (P-CAB), will be presented at the ACG 2021 Annual Scientific Meeting in Las Vegas from October 22-27. The presentation includes insights into acid-related diseases and treatment patterns. Phathom will conduct four poster sessions and one oral presentation while sponsoring a product theater. The company has submitted two NDAs to the FDA for vonoprazan-based regimens targeting H. pylori and plans to submit another NDA for erosive esophagitis treatment by mid-2022.
Phathom Pharmaceuticals (PHAT) announced that vonoprazan met its primary endpoints in the pivotal PHALCON-EE Phase 3 trial, demonstrating superior healing rates compared to lansoprazole in treating erosive esophagitis. Healing rates at Week 8 were 93% for vonoprazan versus 85% for lansoprazole. Additionally, vonoprazan maintained healing at Week 24 with rates of 81% compared to 72% for lansoprazole. A New Drug Application (NDA) is planned for H1 2022 targeting healing and maintenance of erosive esophagitis and heartburn relief, potentially addressing significant unmet needs in the market.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced positive results from its Phase 1 trial (VONO-103), where vonoprazan 20 mg demonstrated superior acid suppression compared to lansoprazole 30 mg over a 7-day period. The study showed a mean 24-hour gastric pH value of 5.9 for vonoprazan versus 3.8 for lansoprazole on Day 7 (p0.0001). Both treatments were well tolerated with no serious adverse events. Phathom is also conducting the Phase 3 PHALCON-EE study, and topline results are expected in October 2021.
Phathom Pharmaceuticals (Nasdaq: PHAT) has secured a $200 million term loan facility from Hercules Capital to bolster its balance sheet ahead of crucial upcoming milestones. The funding allows for a potential commercial launch of vonoprazan, an innovative treatment for acid-related disorders, and extends the company’s cash runway to mid-2023. Key catalysts include pivotal data from the PHALCON-EE Phase 3 trial in October 2021 and plans for regulatory submissions for H. pylori treatments in late 2022.
Phathom Pharmaceuticals (Nasdaq: PHAT) has submitted two new drug applications (NDAs) to the FDA for vonoprazan-based therapies aimed at treating Helicobacter pylori infection in adults. The vonoprazan triple therapy and dual therapy show superior eradication rates compared to current treatments. If approved, Phathom expects to launch these therapies in the U.S. in the latter half of 2022. The submissions follow positive results from the pivotal Phase 3 PHALCON-HP trial, the largest U.S. study for H. pylori. The FDA has also granted these therapies Fast Track designation and qualified infectious disease product status.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced that its executives, including President and CEO Terrie Curran, will engage in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, at 11:00 a.m. ET. The company will also hold one-on-one meetings during the virtual conference from September 9-15, 2021. Phathom focuses on developing innovative treatments for gastrointestinal diseases, notably vonoprazan, a potassium competitive acid blocker in late-stage development for acid-related disorders. Recordings will be available for 90 days following the event.
Phathom Pharmaceuticals (Nasdaq: PHAT) reported Q2 2021 financial results, revealing a net loss of $36.6 million, up from $21.1 million YoY. R&D expenses rose to $21.6 million due to increased clinical trial and CMC costs. General and administrative expenses also climbed to $13.7 million. The company anticipates pivotal Phase 3 data for vonoprazan in erosive esophagitis by October 2021 and Phase 2 data in Q1 2022. Additionally, Phathom is set to submit NDAs for vonoprazan-based regimens for H. pylori in September 2021, with cash reserves of $209.7 million sufficient into Q4 2022.